Cumulative Incidence of Mortality Associated with Cardiovascular-Kidney-Metabolic (CKM) Syndrome

被引:1
|
作者
Claudel, Sophie E. [1 ]
Schmidt, Insa M. [2 ]
Waikar, Sushrut S. [2 ]
Verma, Ashish [2 ]
机构
[1] Boston Med Ctr, Dept Med, Boston, MA USA
[2] Boston Univ, Chobanian & Avedisian Sch Med, Dept Med, Sect Nephrol, Boston, MA 02215 USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2025年
关键词
cardiovascular disease; CKD; diabetes mellitus; epidemiology and outcomes; mortality risk; US ADULTS; OBESITY; EVENTS; STATEMENT; DISEASE; TRENDS;
D O I
10.1681/ASN.0000000637
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Key PointsCardiovascular-kidney-metabolic (CKM) syndrome stages 1-4 were associated with a graded risk of cardiovascular mortality in a nationally representative sample of US adults.Risk was similar between stages 0 and 1, suggesting that stage 1 represents a prime opportunity for prevention and risk mitigation.CKM staging is specific to cardiovascular mortality, given lack of a strong association with either noncardiovascular or cancer mortality.BackgroundIt is imperative to critically evaluate the prognostic implications of cardiovascular-kidney-metabolic (CKM) syndrome staging to inform clinical practice. The primary aims of this study were to define the risk of mortality associated with each CKM syndrome stage and to determine the corresponding restricted mean survival time over a 15-year period.MethodsThis was a longitudinal study of 50,678 community-dwelling US adults aged 20 years and older with baseline data for CKM stage determination participating in the 1999-2018 National Health and Nutrition Examination Survey. CKM stages were defined according to the American Heart Association presidential advisory. Fifteen-year adjusted cumulative incidences of cardiovascular mortality were calculated for each stage from confounder-adjusted survival curves using the G-formula.ResultsOver a median 9.5-year follow-up, 2564 participants experienced cardiovascular death. The 15-year adjusted cumulative incidences of cardiovascular mortality were stage 0, 5.5% (95% confidence interval [CI], 1.8 to 9.3); stage 1, 5.7% (95% CI, 3.2 to 8.2); stage 2, 7.9% (95% CI, 6.8 to 9.1); stage 3, 8.7% (95% CI, 6.7 to 10.8); and stage 4, 15.2% (95% CI, 13.6 to 16.8). The absolute risk difference between CKM stage 4 and stage 0 at 15 years was 9.6% (95% CI, 5.6 to 13.6). The survival difference between CKM stage 0 and stage 4 at 15 years was 8.1 (95% CI, 8.0 to 8.2) months.ConclusionsOur findings reveal a graded risk of cardiovascular mortality associated with higher CKM syndrome stage.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review
    Sebastian, Sneha Annie
    Padda, Inderbir
    Johal, Gurpreet
    CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (02)
  • [2] An Overview of Cardiovascular-Kidney-Metabolic Syndrome
    Ferdinand, Keith C.
    AMERICAN JOURNAL OF MANAGED CARE, 2024, 30 (10) : S181 - S188
  • [3] Association between different stages of cardiovascular-kidney-metabolic syndrome and the risk of all-cause mortality
    Li, Na
    Li, Yaqi
    Cui, Liufu
    Shu, Rong
    Song, Haicheng
    Wang, Jierui
    Chen, Shuohua
    Liu, Bailu
    Shi, Huijing
    Gao, Huanqing
    Huang, Tao
    Gao, Xiang
    Geng, Tingting
    Wu, Shouling
    ATHEROSCLEROSIS, 2024, 397
  • [4] From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework
    Theodorakis, Nikolaos
    Nikolaou, Maria
    BIOMOLECULES, 2025, 15 (02)
  • [5] The Diminished Cardiorespiratory Fitness in Cardiovascular-Kidney-Metabolic Syndrome
    Liu, Yuting
    Liang, Yanting
    Ma, Huan
    Gao, Hengyuan
    Zhang, Xinzhou
    JOURNAL OF MULTIDISCIPLINARY HEALTHCARE, 2025, 18 : 1081 - 1090
  • [6] Overall Sleep Quality Is Associated With Advanced Stages in Patients With Cardiovascular-Kidney-Metabolic Syndrome
    Tu, Dingyuan
    Sun, Jie
    Wang, Pengru
    Xu, Qiang
    Ma, Chaoqun
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2025, 14 (07):
  • [7] Associations of cardiovascular-kidney-metabolic syndrome stages with premature mortality and the role of social determinants of health
    Zhu, Ruixin
    Wang, Ran
    He, Jingjing
    Wang, Langrun
    Chen, Huiyu
    Wang, Yifan
    An, Peng
    Li, Keji
    Ren, Fazheng
    Xu, Weili
    Martinez, J. Alfredo
    Raben, Anne
    Guo, Jie
    JOURNAL OF NUTRITION HEALTH & AGING, 2025, 29 (04)
  • [8] A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association
    Ndumele, Chiadi E.
    Neeland, Ian J.
    Tuttle, Katherine R.
    Chow, Sheryl L.
    Mathew, Roy O.
    Khan, Sadiya S.
    Coresh, Josef
    Baker-Smith, Carissa M.
    Carnethon, Mercedes R.
    Despres, Jean-Pierre
    Ho, Jennifer E.
    Joseph, Joshua J.
    Kernan, Walter N.
    Khera, Amit
    Kosiborod, Mikhail N.
    Lekavich, Carolyn L.
    Lewis, Eldrin F.
    Lo, Kevin B.
    Ozkan, Bige
    Palaniappan, Latha P.
    Patel, Sonali S.
    Pencina, Michael J.
    Powell-Wiley, Tiffany M.
    Sperling, Laurence S.
    Virani, Salim S.
    Wright, Jackson T.
    Singh, Radhika Rajgopal
    Elkind, Mitchell S. V.
    Rangaswami, Janani
    Amer Heart Assoc
    CIRCULATION, 2023, 148 (20) : 1636 - 1664
  • [9] Bilirubin bioconversion to urobilin in the gut-liver-kidney axis: A biomarker for insulin resistance in the Cardiovascular-Kidney-Metabolic (CKM) Syndrome
    Kipp, Zachary A.
    Badmus, Olufunto O.
    Stec, David E.
    Hall, Brantley
    Hinds Jr, Terry D.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2025, 163
  • [10] Association of serum Klotho with the severity and mortality among adults with cardiovascular-kidney-metabolic syndrome
    Tang, Jiao
    Xu, Zhehao
    Ren, Li
    Xu, Jiahua
    Chen, Xin
    Jin, Yian
    Liang, Ruiyun
    Zhang, Huanji
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)